{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:37:38Z","timestamp":1769067458582,"version":"3.49.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2018,10,28]],"date-time":"2018-10-28T00:00:00Z","timestamp":1540684800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,10,28]],"date-time":"2018-10-28T00:00:00Z","timestamp":1540684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["13\/50\/12"],"award-info":[{"award-number":["13\/50\/12"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["PB-PG-1215-20019"],"award-info":[{"award-number":["PB-PG-1215-20019"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006662","name":"National Institute on Handicapped Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1111\/bjd.16717","type":"journal-article","created":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T16:57:42Z","timestamp":1525453062000},"page":"1297-1306","source":"Crossref","is-referenced-by-count":20,"title":["A randomized controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexate vs. ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema Trial (TREAT)"],"prefix":"10.1093","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9048-2044","authenticated-orcid":false,"given":"A.D.","family":"Irvine","sequence":"first","affiliation":[{"name":"Clinical Medicine; Trinity College Dublin; Dublin Ireland"},{"name":"Paediatric Dermatology; Our Lady's Children Hospital Crumlin; Dublin Ireland"},{"name":"National Children's Research Centre; Crumlin, Dublin Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.P.","family":"Jones","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Centre; Department of Biostatistics; University of Liverpool; Liverpool U.K"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Beattie","sequence":"additional","affiliation":[{"name":"Royal Hospital for Children NHS Trust; Glasgow U.K"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Baron","sequence":"additional","affiliation":[{"name":"Unit for Population-Based Dermatology Research; St John's Institute of Dermatology; Guy's and St Thomas\u2019 NHS Foundation Trust and King's College London; London U.K"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Browne","sequence":"additional","affiliation":[{"name":"Paediatric Dermatology; Our Lady's Children Hospital Crumlin; Dublin Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Ashoor","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Centre; Department of Biostatistics; University of Liverpool; Liverpool U.K"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"O'Neill","sequence":"additional","affiliation":[{"name":"Biochemistry; Trinity College Dublin; Dublin Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rosala-Hallas","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Centre; Department of Biostatistics; University of Liverpool; Liverpool U.K"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Sach","sequence":"additional","affiliation":[{"name":"Health Economics Group; Norwich Medical School; University of East Anglia; Norwich U.K"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Spowart","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Centre; Department of Biostatistics; University of Liverpool; Liverpool U.K"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Taams","sequence":"additional","affiliation":[{"name":"Centre for Molecular and Cellular Biology of Inflammation; King's College London; London U.K"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Walker","sequence":"additional","affiliation":[{"name":"Unit for Population-Based Dermatology Research; St John's Institute of Dermatology; Guy's and St Thomas\u2019 NHS Foundation Trust and King's College London; London U.K"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Wan","sequence":"additional","affiliation":[{"name":"Unit for Population-Based Dermatology Research; St John's Institute of Dermatology; Guy's and St Thomas\u2019 NHS Foundation Trust and King's College London; London U.K"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Webb","sequence":"additional","affiliation":[{"name":"Renal Research Laboratories; Manchester Royal Infirmary; Manchester U.K"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Williamson","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Centre; Department of Biostatistics; University of Liverpool; Liverpool U.K"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4884-6286","authenticated-orcid":false,"given":"C.","family":"Flohr","sequence":"additional","affiliation":[{"name":"Unit for Population-Based Dermatology Research; St John's Institute of Dermatology; Guy's and St Thomas\u2019 NHS Foundation Trust and King's College London; London U.K"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the TREAT Trial Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,10,28]]},"reference":[{"key":"10.1111\/bjd.16717-BIB0001|bjd16717-cit-0001","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-2133.1998.02316.x","article-title":"Severity distribution of atopic dermatitis in the community and its relationship to secondary referral","volume":"139","author":"Emerson","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16717-BIB0002|bjd16717-cit-0002","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1046\/j.1468-3083.2002.00495.x","article-title":"Are quality of family life and disease severity related in childhood atopic dermatitis?","volume":"16","author":"Ben-Gashir","year":"2002","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.16717-BIB0003|bjd16717-cit-0003","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00019053-200321020-00003","article-title":"Cost of illness of atopic dermatitis in children: a societal perspective","volume":"21","author":"Kemp","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1111\/bjd.16717-BIB0004|bjd16717-cit-0004","doi-asserted-by":"crossref","first-page":"e4770","DOI":"10.1136\/bmj.e4770","article-title":"Management of difficult and severe eczema in childhood","volume":"345","author":"McAleer","year":"2012","journal-title":"BMJ"},{"key":"10.1111\/bjd.16717-BIB0005|bjd16717-cit-0005","doi-asserted-by":"crossref","first-page":"774.e6","DOI":"10.1016\/j.jaci.2013.03.016","article-title":"Systemic therapies for severe atopic dermatitis in children and adults","volume":"132","author":"Flohr","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/bjd.16717-BIB0006|bjd16717-cit-0006","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/bjd.12505","article-title":"The European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey","volume":"169","author":"Proudfoot","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16717-BIB0007|bjd16717-cit-0007","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jaad.2016.09.021","article-title":"Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey","volume":"76","author":"Totri","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"562-9","key":"10.1111\/bjd.16717-BIB0008|bjd16717-cit-0008","first-page":"e3","article-title":"Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis: a phase III randomized noninferiority trial","volume":"6","author":"Goujon","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1111\/bjd.16717-BIB0009|bjd16717-cit-0009","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00431-012-1893-3","article-title":"Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt","volume":"172","author":"El-Khalawany","year":"2013","journal-title":"Eur J Pediatr"},{"key":"10.1111\/bjd.16717-BIB0010|bjd16717-cit-0010","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jaci.2011.03.024","article-title":"A randomized trial of methotrexate versus azathioprine for severe atopic eczema","volume":"128","author":"Schram","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/bjd.16717-BIB0011|bjd16717-cit-0011","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/bjd.16240","article-title":"Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial","volume":"178","author":"Gerbens","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16717-BIB0012|bjd16717-cit-0012","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1365-2133.2012.10873.x","article-title":"Commentary: are methotrexate and azathioprine really equivalent for treating severe atopic eczema?","volume":"166","author":"Williams","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16717-BIB0013|bjd16717-cit-0013","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaci.2013.07.049","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review","volume":"133","author":"Roekevisch","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/bjd.16717-BIB0014|bjd16717-cit-0014","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/pde.13209","article-title":"Methotrexate for severe childhood atopic dermatitis: clinical experience in a tertiary center","volume":"34","author":"Dvorakova","year":"2017","journal-title":"Pediatr Dermatol"},{"key":"10.1111\/bjd.16717-BIB0015|bjd16717-cit-0015","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 Statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1111\/bjd.16717-BIB0016|bjd16717-cit-0016","volume-title":"BNF for Children 2014-15","author":"Paediatric Formulary Committee","year":"2014"},{"key":"10.1111\/bjd.16717-BIB0017|bjd16717-cit-0017","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1365-2133.2000.03241.x","article-title":"Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy","volume":"142","author":"Harper","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16717-BIB0018|bjd16717-cit-0018","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1097\/MIB.0000000000000102","article-title":"Retrospective cohort study of methotrexate use in the treatment of pediatric Crohn's disease","volume":"20","author":"Sunseri","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/bjd.16717-BIB0019|bjd16717-cit-0019","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/acr.21697","article-title":"Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry","volume":"64","author":"Klein","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1111\/bjd.16717-BIB0020|bjd16717-cit-0020","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1002\/ibd.21653","article-title":"Methotrexate in the treatment of inflammatory bowel disease: an 8-year retrospective study in a Canadian pediatric IBD center","volume":"17","author":"Willot","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/bjd.16717-BIB0021|bjd16717-cit-0021","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/01.mib.0000235103.47280.bb","article-title":"Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study","volume":"12","author":"Uhlen","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/bjd.16717-BIB0022|bjd16717-cit-0022","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.16717-BIB0023|bjd16717-cit-0023","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jval.2015.02.001","article-title":"Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force Report","volume":"18","author":"Ramsey","year":"2015","journal-title":"Value Health"},{"key":"10.1111\/bjd.16717-BIB0024|bjd16717-cit-0024","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"key":"10.1111\/bjd.16717-BIB0025|bjd16717-cit-0025","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"10.1111\/bjd.16717-BIB0026|bjd16717-cit-0026","unstructured":"National Institute for Health and Care Excellence Guide to the methods of technology appraisal 2013 https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword"},{"key":"10.1111\/bjd.16717-BIB0027|bjd16717-cit-0027","unstructured":"Personal Social Services Research Unit (PSSRU) Unit costs of health and social care 2016. Compiled by Lesley Curtis and Amanda Burns https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/unit-costs-2016\/"},{"key":"10.1111\/bjd.16717-BIB0028|bjd16717-cit-0028","unstructured":"Department of Health and Social Care NHS reference costs 2015 to 2016 https:\/\/www.gov.uk\/government\/publications\/nhs-reference-costs-2015-to-2016"},{"key":"10.1111\/bjd.16717-BIB0029|bjd16717-cit-0029","unstructured":"NHS Digital Prescription cost analysis, England 2016 http:\/\/webarchive.nationalarchives.gov.uk\/20180328140312"},{"key":"10.1111\/bjd.16717-BIB0030|bjd16717-cit-0030","unstructured":"Office for National Statistics Annual survey of hours and earnings 2016 https:\/\/www.ons.gov.uk\/employmentandlabourmarket\/peopleinwork\/earningsandworkinghours\/bulletins\/annualsurveyofhoursandearnings\/2016provisionalresults"},{"key":"10.1111\/bjd.16717-BIB0031|bjd16717-cit-0031","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s11136-009-9524-9","article-title":"Developing a descriptive system for a new preference-based measure of health-related quality of life for children","volume":"18","author":"Stevens","year":"2009","journal-title":"Qual Life Res"},{"key":"10.1111\/bjd.16717-BIB0032|bjd16717-cit-0032","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hec.944","article-title":"Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility","volume":"14","author":"Manca","year":"2005","journal-title":"Health Econ"},{"key":"10.1111\/bjd.16717-BIB0033|bjd16717-cit-0033","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/hec.843","article-title":"Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data","volume":"13","author":"Willan","year":"2004","journal-title":"Health Econ"},{"key":"10.1111\/bjd.16717-BIB0034|bjd16717-cit-0034","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/hec.903","article-title":"Cost-effectiveness acceptability curves - facts, fallacies and frequently asked questions","volume":"13","author":"Fenwick","year":"2004","journal-title":"Health Econ"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.16717","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.16717\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:41:22Z","timestamp":1676382082000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/179\/6\/1297\/6731044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,28]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.16717","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10,28]]}}}